Celcuity (NASDAQ:CELC) Given New $115.00 Price Target at Stifel Nicolaus

Celcuity (NASDAQ:CELC) had its price objective upped by stock analysts at Stifel Nicolaus from $68.00 to $115.00 in a research note issued to investors on Thursday,Benzinga reports. The firm currently has a “buy” rating on the stock. Stifel Nicolaus’ target price suggests a potential upside of 31.68% from the stock’s previous close.

Several other research analysts have also commented on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Celcuity in a research report on Wednesday, October 8th. Guggenheim started coverage on Celcuity in a research note on Monday, September 22nd. They set a “buy” rating on the stock. Needham & Company LLC set a $95.00 target price on shares of Celcuity in a report on Monday, October 20th. Wall Street Zen downgraded shares of Celcuity from a “hold” rating to a “sell” rating in a research report on Sunday, October 26th. Finally, Leerink Partners raised their target price on shares of Celcuity from $28.00 to $60.00 and gave the stock an “outperform” rating in a report on Monday, July 28th. Five research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $86.75.

Celcuity Trading Up 2.6%

NASDAQ CELC traded up $2.19 during mid-day trading on Thursday, reaching $87.34. 458,099 shares of the stock were exchanged, compared to its average volume of 724,337. The stock has a market capitalization of $3.71 billion, a PE ratio of -25.21 and a beta of 0.72. The company has a debt-to-equity ratio of 2.24, a quick ratio of 4.58 and a current ratio of 4.58. Celcuity has a 1-year low of $7.57 and a 1-year high of $87.74. The business’s fifty day simple moving average is $60.24 and its 200 day simple moving average is $35.85.

Celcuity (NASDAQ:CELC) last issued its earnings results on Wednesday, November 12th. The company reported ($0.92) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.05) by $0.13. The firm had revenue of $0.15 million during the quarter. On average, research analysts anticipate that Celcuity will post -2.62 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Celcuity

Several hedge funds and other institutional investors have recently made changes to their positions in CELC. Ogorek Anthony Joseph NY ADV bought a new stake in shares of Celcuity in the third quarter worth about $27,000. US Bancorp DE grew its position in Celcuity by 25.4% in the third quarter. US Bancorp DE now owns 706 shares of the company’s stock valued at $35,000 after purchasing an additional 143 shares in the last quarter. BNP Paribas Financial Markets boosted its position in Celcuity by 78.9% during the second quarter. BNP Paribas Financial Markets now owns 2,647 shares of the company’s stock valued at $35,000 after purchasing an additional 1,167 shares during the last quarter. Tower Research Capital LLC TRC grew its position in shares of Celcuity by 211.2% in the 2nd quarter. Tower Research Capital LLC TRC now owns 5,549 shares of the company’s stock valued at $74,000 after acquiring an additional 3,766 shares during the period. Finally, Avanza Fonder AB bought a new stake in Celcuity in the 3rd quarter valued at $79,000. 63.33% of the stock is owned by institutional investors and hedge funds.

Celcuity Company Profile

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.